Stephen Harnicar

发表

Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort study

J. Wills, G. Soff, G. Brar, 2016, Journal of Thrombosis and Thrombolysis.

Pharmacotherapy for chronic myelogenous leukemia: a case-based approach.

Stephen Harnicar, 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

Spotlight on nilotinib in the treatment of chronic myelogenous leukemia

Stephen Harnicar, Sherry P Mathew, 2014 .

Modification of vincristine dosing during concomitant azole therapy in adult acute lymphoblastic leukemia patients

J. Jurcic, N. Adel, Stephen Harnicar, 2009, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Intensified Mycophenolate Mofetil Dosing and Higher Mycophenolic Acid Trough Levels Reduce Severe Acute Graft-versus-Host Disease after Double-Unit Cord Blood Transplantation.

M. Perales, R. Jenq, M. V. D. van den Brink, 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Clinical Research : Alternative Donors Intensi fi ed Mycophenolate Mofetil Dosing and Higher Mycophenolic Acid Trough Levels Reduce Severe Acute Graft-versus-Host Disease after Double-Unit Cord Blood Transplantation

M. Perales, R. Jenq, S. Devlin, 2022 .

Pharmacokinetics and Toxicities after Evomela® (propylene glycol free melphalan) with Autologous Hematopoietic Stem Cell Transplant (AHCT) for Multiple Myeloma and AL Amyloidosis

S. Devlin, S. Giralt, H. Landau, 2017 .

Rivaroxaban for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation and Active Cancer.

J. Wills, Dipti Gupta, G. Soff, 2016, The American journal of cardiology.

Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors

A. Drilon, M. Offin, Bob T. Li, 2018, Therapeutics and clinical risk management.

Prescribing trends with daptomycin (cubicin) for the treatment of gram-positive infections.

Stephen Harnicar, Noreen H Chan Tompkins, 2008, P & T : a peer-reviewed journal for formulary management.

Characterization, management, and risk factors of hyperglycemia during PI3K or AKT inhibitor treatment

A. Drilon, J. Harding, K. Jhaveri, 2022, Cancer medicine.

Outpatient clinical pharmacy practice in the face of COVID-19 at a cancer center in New York City

Phuong Dao, L. Buie, Jennifer Thackray, 2021, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Oncology pharmacy practice in the United States: Results of a comprehensive, nationwide survey

Stephen Harnicar, G. Riebandt, Shannon M Hough, 2023, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Treatment of central venous catheter‐associated deep venous thrombosis in cancer patients with rivaroxaban

J. Wills, G. Soff, S. Mantha, 2016, American journal of hematology.

Treatment of central venous catheter‐associated deep venous thrombosis in cancer patients with rivaroxaban

Lauren E. Molloy, J. Wills, G. Soff, 2016, American journal of hematology.